


HER2 陽性・65 歳以上の進行再発胃癌に対する
ティーエスワン+トラスツズマブ併用療法の第 II 相試験(JACCRO GC-06)が
Gastric Cancer に掲載されました

Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06)

Yutaka Kimura¹ · Masashi Fujii² · Toshiki Masuishi³ · Kazuhiro Nishikawa⁴ · Chikara Kunisaki⁵ ·
Satoshi Matsusaka⁶ · Yoshihiko Segawa⁷ · Masato Nakamura⁸ · Kinro Sasaki⁹ · Narutoshi Nagao¹⁰ ·
Yukimasa Hatachi¹¹ · Yasuhiko Yuasa¹² · Shinya Asami¹³ · Masahiro Takeuchi¹⁴ · Hiroshi Furukawa¹ ·
Toshifusa Nakajima² · on behalf of the JACCRO GC-06 Study Group

Gastric Cancer

DOI 10.1007/s10120-017-0766-x



Conclusion

We conclude that trastuzumab plus S-1 alone without cisplatin is an effective and safe treatment that can prolong survival in elderly patients with HER2-positive AGC.

日本がん臨床試験推進機構 (Japan Clinical Cancer Research Organization: JACCRO)

「JACCRO は臨床研究の裾野を広げることを目標にしています」